Oxford Biomedica

Creating a Global Viral Vector Champion

January 2022

Disclaimer

THIS PRESENTATION AND ITS CONTENTS ARE STRICTLY CONFIDENTIAL. BY ATTENDING THE MEETING (INCLUDING ANY VIRTUAL MEETING CONDUCTED VIA ELECTRONIC MEANS) WHERE THIS PRESENTATION IS MADE, OR BY READING THE PRESENTATION SLIDES, YOU AGREE TO BE BOUND BY THE FOLLOWING CONDITIONS AND TO MAINTAIN ABSOLUTE CONFIDENTIALITY REGARDING THE INFORMATION CONTAINED IN THIS PRESENTATION.

The information, statements and opinions contained in this Presentation do not constitute or form part of a public offer under any applicable legislation or any offer or solicitation to purchase or subscribe for securities in the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia) (the "United States"), Australia, Canada, New Zealand, Japan or the Republic of South Africa. This Presentation is not for release, publication or distribution, directly or indirectly, in the United States, Australia, Canada, New Zealand, Japan, the Republic of South Africa or any other jurisdiction where such distribution or offer is unlawful, except in the United States to qualified institutional buyers as defined in Rule 144A under the US Securities Act of 1933, as amended (the "US Securities Act") ("QIB").

The purpose of this presentation is to provide an overview of Oxford Biomedica plc (the "Company"). This Presentation has been prepared and issued by, and is the sole responsibility of, the Company and is being furnished to each recipient solely for its own information and in connection with meetings with certain institutional investors. For the purposes of this notice, "Presentation" means this document, its contents or any part of it, any oral presentation, any question or answer session and any written or oral material discussed or distributed during the Presentation meeting (including any virtual meeting conducted via electronic means). This Presentation and the information contained herein may not be disclosed, taken away, reproduced, recorded, redistributed, transmitted, copied or passed on, directly or indirectly to any other person or published or used in whole or in part, for any purpose. No copy of this Presentation will be left behind after the meeting. This Presentation and its contents are confidential and you and your directors, officers, employees, agents and affiliates must hold this Presentation and any oral information provided in connection with this Presentation in strict confidence.

This Presentation is not a prospectus or similar offer document. This Presentation does not purport to contain comprehensive or complete information about the Company and is qualified in its entirety by the business, financial and other information the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on London Stock Exchange plc (the "Exchange Information"). Any decision to invest in any securities of the Company should only be made on the basis of a thorough examination of the Exchange Information, which is the sole responsibility of the Company, and an independent investigation of the Company itself and not on the basis of this Presentation. Neither this Presentation nor any of the Exchange Information has been independently verified by any other person unless expressly stated herein or therein.

None of Peel Hunt LLP ("Peel Hunt") and WG Partners LLP ("WG"), or any of their respective directors, officers, employees, advisers and agents accept any responsibility or liability whatsoever for/or makes any representation or warranty, express or implied, as to the truth, fullness, accuracy or completeness of the information in this Presentation (or whether any information has been omitted from the Presentation) or any other information relating to the Company or its associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this Presentation or its contents or otherwise arising in connection therewith. Peel Hunt and WG are acting exclusively for the Company and no one else in connection with this matter and will not regard any other person as their client in relation to such matter. No representation or warranty, express or implied, is given by or on behalf of the Company or any of its directors, officers, employees, agents, affiliates or advisers as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this Presentation or otherwise made available nor as to the reasonableness of any information contained herein or therein and no responsibility or liability (including in respect of direct, indirect or consequential loss or damage) is assumed by any such persons for such information or opinions or for any errors or omissions.

Except where otherwise indicated in this Presentation, the information provided herein is based on matters as they exist at the date of preparation of this Presentation and not as of any future date. All information presented or contained in this Presentation is subject to updating, revision, correction, verification, completion and amendment without notice. Any opinions expressed in this Presentation are subject to change without notice. None of the Company, Peel Hunt, WG, or any of their respective directors, officers, employees, agents, affiliates or advisers is under any obligation to update, complete, revise or keep current the information contained in this Presentation or to which it relates or to provide the recipient of it with access to any additional information that may arise in connection with it. The Presentation does not constitute an audit or due diligence review and should not be construed as such. This Presentation has not been approved by any regulatory or supervisory authority.

Certain industry and market data contained in this Presentation has come from official or third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, none of the Company, Peel Hunt, WG, or any of their respective advisers or representatives has independently verified the data contained therein. In addition, certain of the industry and market data contained in this Presentation come from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice.

This Presentation does not constitute or form part of, and should not be construed as (i) an offer, solicitation or invitation to subscribe for, sell or issue, underwrite or otherwise acquire any securities or financial instruments, nor shall it, or the fact of its communication, form the basis of, or be relied upon in connection with, or act as any inducement to enter into any contract or commitment whatsoever with respect to such securities or financial instruments or (ii) any form of financial opinion, recommendation or investment advice with respect to any securities or financial instruments. The recipient must make its own independent assessment and such investigations as it deems necessary.

Any securities referred to in this Presentation have not been, and will not be, registered under the US Securities Act or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act. There will be no public offering of securities in the United States. Subject to certain limited exceptions, neither this Presentation nor any copy of it may be taken, transmitted or distributed, directly or indirectly, in or into the United States. Any failure to comply with the foregoing restrictions may constitute a violation of US securities laws. The distribution of this Presentation in other jurisdictions may be restricted by law and persons into whose possession this Presentation comes should inform themselves about, and observe, any such restrictions.

This Presentation is only addressed to and directed at (A) persons in member states of the European Economic Area who are "qualified investors" within the meaning of article 2(e) of Regulation (EU) 2017/1129; (B) persons in the United Kingdom who are "qualified investors" within the meaning of article 2(e) of Regulation (EU) 2017/1129, which forms part of UK domestic law pursuant to the European Union (Withdrawal) Act 2018, as amended (the "EUWA"), who (i) have professional experience in matters relating to investments who fall within the definition of "investment professionals" in article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or, (ii) are high net worth companies, unincorporated associations or partnerships or trustees of high value trusts as described in Article 49(2) of the Order; (C) a limited number of persons in the United States that are QIBs; and (D) persons to whom it may otherwise be lawfully communicated (all such persons listed in (A) to (D), together being referred to as "Relevant Persons").

If you have received this Presentation and you are not a Relevant Person, you must return this Presentation immediately to the Company.

This Presentation includes forward-looking statements that reflect the Company's current expectations regarding future events, including the clinical development and regulatory clearance of the Company's product candidates, the Company's ability to find partners for the development and commercialisation of its product candidates, the business of the Company and management plans and objectives. The Company considers any statements that are not historical facts as ''forward-looking statements''. Actual events could differ materially from those projected herein and depend on a number of factors, including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of pre-clinical and clinical studies with respect to the Company's product candidates, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of product candidates, as well as the achievement of expected synergies from such transactions, the acceptance of product candidates by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions and the ability of the Company to identify and consummate suitable strategic and business combination transactions

When used in the Presentation the words ''estimate'', ''project'', ''intend'', ''aim'', ''anticipate'', ''believe'', ''expect'', ''should'' and similar expressions, as they relate to the Company or the management of the Company, are intended to identify such forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this document. Each of the Company, Peel Hunt, WG, and any of their respective directors, officers, employees, agents, affiliates or advisers expressly disclaims any obligation or undertaking to release any update of, or revisions to, any forward-looking statements in this Presentation, save in respect of any requirement under applicable laws, the Listing Rules, Prospectus Regulation Rules, Disclosure and Transparency Rules and other regulations.

Certain information contained in this Presentation may constitute inside information for the purposes of the Criminal Justice Act 1993 and the EU Market Abuse Regulation (2014/596/EU) (as it forms part of UK domestic law by virtue of the EUWA) ("UK MAR"). You agree and accept that you will not deal or encourage any other person to deal in the securities of the Company whilst you remain in possession of such inside information (i.e., until the transaction and other inside information described in the Presentation is announced or until the Company has confirmed to you that you are no longer in possession of inside information) and will not engage in behaviour which would amount to market abuse. Dealing in securities of the Company when in possession of inside information could result in liability under the insider dealing restrictions set out in the Criminal Justice Act 1993 or UK MAR.

Each of Peel Hunt and WG, which are authorised and regulated in the United Kingdom by the Financial Conduct Authority is acting exclusively for the Company and no one else in connection with this Presentation or any future transaction in connection with it. None of Peel Hunt or WG will regard any other person (whether or not a recipient of this Presentation) as a client or will be responsible to anyone other than the Company for providing the protections afforded to its clients or for the giving of advice in relation to the contents of this Presentation or any transaction, matter or arrangement referred to in this Presentation.

By attending the meeting (including any virtual meeting conducted via electronic means) where this Presentation is made you warrant, represent, acknowledge and agree to and with the Company, Peel Hunt and WG that (i) you are a Relevant Person, (ii) you have read, agree to and will comply with the contents of this disclaimer including, without limitation, the obligation to keep this Presentation and its contents confidential and (iii) you will not at any time have any discussion, correspondence or contact concerning the information in this Presentation with any of the directors or employees of the Company or with any of their suppliers in respect of the Company without the prior written consent of the Company.


A Life Saving
Cell and
Gene Therapy
Company

A Leading Viral Vector Specialist Using Science to Save Lives

Delivering on Our Strategy to Become a Global Fully Integrated Viral Vector Platform

Proprietary platform

IP: patents and know-how

Quality Systems

Expertise

Facilities

Process development and manufacturing provides multiple revenue streams

Commercial Stage Viral Vector CDMO with >25 years Experience

19 **Partner Programmes**

Gene Therapeutics

Delivering innovative therapies

5 **Proprietary Products**

AstraZeneca · Bristol Myers Squibb · Boehringer Ingelheim · Orchard therapeutics · ARCELLX · NOVARTIS · Santen · gt UK Cystic Fibrosis Gene Therapy Consortium · Beam Therapeutics · Cabaletta Bio · SIO Gene Therapies · Oxford Biomedica

Oxford Biomedica

Science Based Innovative CDMO with a Proprietary Pipeline

1

A leader in viral vectors within the fast-growing cell and gene therapy industry

First FDA approved lentiviral vector-based gene delivery system through our collaboration with Novartis on Kymriah®

Multiple partnerships with leading companies

AstraZeneca · Bristol Myers Squibb · NOVARTIS · Boehringer Ingelheim

2

Diversified business with CDMO revenues and upside from our proprietary pipeline

CDMO operations and regulatory approved facilities provide multiple revenue streams

Leveraging expertise to deliver innovative therapies through our proprietary pipeline

3

Established operational infrastructure and proven commercial supply capabilities

Proven commercial supply capability in 30 countries

FDA · Pmda · MHRA · European Medicines Agency

Over 740 staff located at 6 UK-based facilities covering in excess of 200,000 sqft[1]

1. Includes manufacturing, laboratory and office space

Oxford Biomedica

Viral Vector Manufacturing to Continue its Growth Trajectory

Global Viral Vector Supply (Outsourced)[1]

(In $ billions)



Oxford Biomedica's goal is to become a global viral vector champion – offering customers expertise and manufacturing capabilities across key vector types

1. Source: Company estimates and third party research

Oxford Biomedica

Oxford Biomedica Solutions AAV Manufacturing and Innovation Business

Oxford Biomedica AAV Manufacturing and Innovation Business: A High Performing Process Development and Manufacturing Platform

Location

Boston, Massachusetts, United States

Employees

Team of c.125 with AAV manufacturing expertise

Manufacturing Capabilities

Process / Analytical Development & early stage clinical manufacturing at 500L, proven scalability to 2,000L for commercial supply

25,000 sq.ft

Manufacturing Capacity & Facility

State-of-the-art GMP facility

10 – 15 500L batches
10 – 15 1,000L batches
annually at steady state[1]

Platform & IP

Proprietary 'plug and play' manufacturing process and platform

c.$25m (£19m)

Contracted Revenues

Minimum contracted revenues in the first full twelve months of operation

Profitability

Break-even expected by year 3 with gold standard long term target margins

1. Company estimates
GBP:USD = 1.33726

Oxford Biomedica

Strategic Rationale for Oxford Biomedica AAV Manufacturing and Innovation Business

1

Broadening Viral Vector Capabilities into AAV

2

US Presence

Technological and Operational Synergies Across Platforms

3

Accretive to Top-Line Growth

4

Oxford Biomedica

1 Broadens Viral Vector Capabilities into the Largest and Fast Growing AAV Segment

Single transaction to bring fully established manufacturing AAV technologies, IP, capabilities and capacity into Oxford Biomedica

Opportunity to leverage commercial capabilities in Oxbox through increased credibility in AAV with Oxford Biomedica AAV Manufacturing and Innovation Business

AAV segment poised for outsized growth: 25% CAGR (2022 – 2026)[1]

Oxford Biomedica AAV Manufacturing and Innovation Business is a high performing full scope AAV solutions provider

Proven end-to-end capabilities spanning early AAV vector design and process development for discovery programmes through clinical trials and proven scalability for commercial supply

Process development expertise covers all AAV related gene therapy and gene editing development functions

Established early-stage clinical manufacturing, supported three successful Phase I trial initiations in the US





1. Company estimates and third party research

Oxford Biomedica

2 Expands Geographic Presence and Technical Operational Expertise in the Key US Biopharma Market

- Immediate expansion of presence in the US: Boston presents ideal access to key US Biotech & Pharma Hub
- Established early-stage clinical manufacturing – largest AAV sub-segment
- Successfully supported 3 AAV novel products, CMC requirement met for each IND
- c.125 Boston based technical operations employees with deep AAV development and manufacturing know-how
- Full suite of analytical and testing capabilities includes full suite of analytical methods
- Opportunity for cross-selling of lentiviral vector manufacturing capabilities to Oxford Biomedica Solutions AAV Manufacturing and Innovation Business customers

Number of AAV Products – By Pipeline Phase[1]



US-based AAV C&GT Product Development Companies

1. As of Jan-22, US companies only

Source: Company, Evaluate Pharma

Oxford Biomedica

3 Opportunity to Leverage Oxford Biomedica Technologies and IP in AAV to Further Enhance Platform

	Transfection	Upstream & Downstream	Analytical Testing	Cell Technology
AAV Manufacturing and Innovation Business Technology	Triple Plasmid System	Scalable to 500L & 2,000L	Full suite of methods established	HEK293 cells for transient production
Oxford Biomedica Technology	More stable transfection mix	Perfusion technology TRiPSystem™ SecNuc™	Assay automation Advanced analytics (mass spectrometry)	LentiStable™
Technical Synergies	Lower material costs Improved quality Easier scale up >500L	Higher yields per batch Restore high AAV titre Lower DNA impurities	Faster, more efficient testing Leading in vector characterisation	Opportunity for AAV stable cell line development

Collaborative and complementary AAV and lentiviral vector-based approach has the potential to accelerate the mission to improve patients' lives worldwide

Oxford Biomedica

4 Immediately Accretive to Revenue Growth with Contribution from Homology Medicines and Customer Pipeline

Current Capacity

10 – 15 500L batches
10 – 15 1,000L batches
annually at steady state[1]

Underwritten Demand and Pipeline

3-year strategic partnership with Homology for AAV manufacturing provides Oxford Biomedica AAV Manufacturing and Innovation Business its first major customer

Synergies

Scope to leverage presence and capabilities across Homology and new customers – increases revenue potential

Innovation in C&GT Development

Strong anticipated customer demand for high quality vector manufacturing

131 AAV GT companies active globally

FDA expects to be approving 10-20 regenerative medicines[2] annually by 2025

Regulatory Environment

Escalating quality requirements driving demand for partners with track record

1. Company estimates
2. FDA statement, 15 January 2019, Regenerative medicines including cell and gene therapies

Source: Company, Evaluate Pharma, FDA

Oxford Biomedica

Transaction Overview

Transaction Overview

Oxford Biomedica and Homology Medicines will form Oxford Biomedica Solutions LLC[1] ("Oxford Biomedica Solutions"), a new US-based AAV manufacturing and innovation business

Homology Medicines will bring its established AAV process development and manufacturing platform, strong IP, experienced team and US-based GMP facility to Oxford Biomedica Solutions

Oxford Biomedica Solutions' AAV Manufacturing and Innovation Business will offer a scalable, high quality manufacturing platform to global customers, including Homology Medicines through a multi-year supply agreement

- Minimum first twelve months contracted revenues of c.$25m (£19m) from Homology Medicines
- c.$35m (£26m) worth of gross assets to be transferred by Homology Medicines to Oxford Biomedica Solutions at closing

Transaction implies a pre-money Enterprise Value of c.$175m (£131m) for Oxford Biomedica Solutions

Transaction Structure

Oxford Biomedica US to acquire 80% stake in newly-formed Oxford Biomedica Solutions for $130m (£97m) cash consideration and a $50m (£37m) capital injection into Oxford Biomedica Solutions to fund growth

Homology Medicines will retain 20% upon completion of transaction

At any time following the three-year anniversary of closing, Oxford Biomedica will have a call option to purchase, and Homology Medicines will have a put option to require Oxford Biomedica to purchase, Homology Medicines' ownership interest[2]

Governance, Leadership and Incentivisation

LLC agreement between Oxford Biomedica and Homology Medicines, under which Oxford Biomedica will have control of Oxford Biomedica Solutions' AAV Manufacturing and Innovation Business through a majority board position

Complementary cultures focused on science-led solutions and excellence in customer service

Tim Kelly, Chief Operating Officer of Homology Medicines, will join Oxford Biomedica Solutions' AAV Manufacturing and Innovation Business as Chief Executive Officer and Chair of its Board of Directors and will also become a member of Oxford Biomedica's Senior Executive Team

Oxford Biomedica Solutions employees to be provided with an attractive incentivisation package upon completion

Closing and Conditions

Transaction is expected to close in Q1'22, subject to the satisfaction of requirements of the Hart-Scott-Rodino Antitrust (HSR) Improvements Act of 1976

Transaction is not conditional on Oxford Biomedica shareholder vote or on financing

1. Legal entity is Roadrunner Solutions LLC, which will be renamed Oxford Biomedica Solutions LLC on completion
2. Price payable by Oxford Biomedica on exercise of either option will be based on a valuation equivalent to a multiple of 5.5x revenue attributable to Oxford Biomedica Solutions over the twelve months prior to the date of exercise. Maximum payable by Oxford Biomedica on exercise of the put/call will be capped at an amount equal to US$74.1 million (£55.4 million) resulting in the maximum consideration payable for 100 per cent. of Oxford Biomedica Solutions being US$254.1 million (£190.0 million)

GBP:USD = 1.33726

Oxford Biomedica + AAV Manufacturing and Innovation Business: A Global Viral Vector Champion

1. **Creates a leading partner of choice with advanced capabilities across key vector types**
2. **Track record, skills and expertise in a significantly larger total addressable market**
3. **Addressing the increasing market requirements for efficacy, safety and affordability in C&GT**
4. **Technologies and IP to continue innovation to further enhance platform and customer offering**
5. **Strong synergy opportunities from combination of technical capabilities and cross-selling to existing customers in attractive end markets**

Contact Us

Oxford Biomedica plc
Windrush Court
Transport Way
Oxford
OX4 6LT

Stuart Paynter Chief Financial Officer
Sophia Bolhassan Head of IR

+44 (0) 1865 783 000
IR@oxb.com
www.oxb.com

Appendix

Financing Transaction Summary

Issuer	**Oxford Biomedica**	
Ticker / Listing	OXB / London Stock Exchange Main Market Premium Segment, FTSE250	
Acquisition	Classified as Class 2 under the Listing Rules, subject to Hart Scott Rodino review $180m (£135m) financing requirement for the transaction, Oxford Biomedica's cash balances at 31 December 21 were c.£109m Oxford Biomedica has entered into a commitment letter for a senior secured short term loan facility of $85m (£64m). Interest rate under the terms will be 8.50% p.a. payable quarterly in cash or in kind, at the option of the company	
Placing	Proposed placing to raise approx. £80m by way of an institutional placing and a retail offer	
Structure / Timing	• Placing (conditional only on admission) of up to c.4.858m new ordinary shares using existing authorities (c.5.6% of ISC) • A further number of new ordinary shares will, subject to shareholder approval, be issued under the new authorities to be sought at the General Meeting to issue ordinary shares for cash on a non-pre-emptive basis • Dr. Roch Doliveux to invest a minimum of £1m	
Use of Proceeds	• The net proceeds of the Placing, the short term loan facility and the company's existing cash resources will fund: I. Acquisition of 80% ownership interest in newly-formed Oxford Biomedica Solutions ($180m or £135m) II. The Company's existing capital requirements in respect of Oxbox and the Windrush Innovation Centre est. £65m III. Working capital and expenses	
Joint Bookrunners	Peel Hunt LLP and WG Partners LLP	
Indicative Timetable (precise details to be confirmed upon posting of the circular to shareholders)	Announcement of the results of the placing	28 January 2022
	Settlement date for Firm Placing shares	4 February 2022
	Posting of circular in connection with the Placing	Mid February 2022
	General Meeting	Early March 2022
	Completion of Acquisition	Week commencing 7 March 2022, subject to HSR
	Admission of Conditional Placing shares	On or around 11 March 2022

GBP:USD = 1.33726

Oxford Biomedica
Business Update

- Simultaneous to announcing the transaction, John Dawson will step down as CEO and Roch Doliveux will become interim CEO
  - Roch Doliveux has been integrally involved with Oxford Biomedica's strong senior management team and has significant experience of running international companies (including post-transaction integration), having previously been CEO at UCB for ten years
  - John Dawson will remain a Board Director and Advisor to the Company
  - Process to appoint a new CEO is underway
- FY'21 Group revenues expected to be in line with consensus[1], closing cash position at 31st December 2021 of c.£109 million (unaudited)
- Continued strong momentum across CDMO activities since H1 2021:
  - Boehringer Ingelheim option exercised, new agreements with Arcellx and Cabaletta Bio and extension and update to the Novartis agreement providing freedom for the Group to work with other partners in three CAR-T targets
  - Ongoing discussions with other potential partners including one at an advanced stage
  - Ongoing discussions with AstraZeneca on potential extension of the current 18 month manufacturing agreement

1. Bloomberg consensus FY21 revenues: c.£160m (as of the latest practicable date)

Access to Well Established CMC is Paramount in Cell and Gene Therapy

1. C&GT industry is witnessing an increase in clinical development delays due to manufacturing issues
2. Regulators are requesting more information about production processes
3. Improvements in the assessments of manufacturing quality driven by technological advancements in measuring purity and potency of therapeutics
4. The number of gene therapies available to patients is expected to increase, driving the need for innovative solutions to manufacturing challenges
5. CMC requirements for testing, reporting and clinical submissions can place an undue burden on developers
6. Shorter development timelines, driven by the availability of expedited approval pathways, increase the importance of partnering with a trusted viral vector CDMO early on in the development process

US Gene Therapy Clinical Holds[1]



"Despite the promise in these gene therapies, the FDA has flagged safety concerns ranging from liver toxicity to kidney injury to a loss of neurons. These issues have long been noted as gene therapies moved toward market and patients died during earlier clinical trials."

FIERCE Biotech

1. List is not exhaustive and excludes clinical holds for CAR-T / Cell therapies

Source: Fierce biotech, Evaluate Pharma, Companies' press releases, filings

Oxford Biomedica

Oxford Biomedica
Proprietary Platform Innovation

Maximising data integration and analysis

AI and machine learning

Targeted vectors with optimal/regulated expression



Cell and vector engineering to increase capability and productivity

Automation for increased productivity



Therapeutic vectors with tailored attributes





Proteomics/ transcriptomics

Analytical dev. to characterise vectors (purity) and achieve rapid batch release



Process C: Higher titre and superior quality – Includes Perfusion, U1 (RNA) & U2

LentiStable™

SecNuc™

TRiPSystem™

Large scale bioprocessing: Increase yield and improve purity



Process D: Producer cell lines

Oxford Biomedica

Oxford Biomedica
CDMO Pipeline – Page 1 of 2

Product	Indication	Pre-Clinical	Phase I	Phase I/II	Phase II	Phase III	Approval
LentiVector® platform							
Kymriah®[1]	r/r ALL / r/r DLBCL						
2nd CAR-T	Cancer (multiple)						
3rd CAR-T	Cancer (multiple)						
4th CAR-T	Cancer (multiple)						
5th CAR-T	Cancer (multiple)						
6th CAR-T	Cancer (multiple)						
AXO-Lenti-PD[2]	Parkinson's disease						
1st CAR-T / TCR-T	Undisclosed						
2nd CAR-T / TCR-T	Undisclosed						
3rd CAR-T / TCR-T	Undisclosed						
4th CAR-T / TCR-T	Undisclosed						

Process development and bioprocessing revenues, and royalties

NOVARTIS

SIO GENE THERAPIES

Bristol Myers Squibb

In vivo programmes *Ex vivo programmes*

1. USAN name is tisagenlecleucel
2. AXO-Lenti-PD formerly known as OXB-102, which OXB out-licensed to Sio Gene Therapies

Oxford Biomedica

Oxford Biomedica
CDMO Pipeline – Page 2 of 2

Product	Indication	Pre-Clinical	Phase I	Phase I/II	Phase II	Phase III	Approval
LentiVector® platform							
OTL-201	MPS-IIIA						
Other	undisclosed						
CAR-T	Cancer (multiple)						
CAR-T	Undisclosed						
CAAR-T	mPV (autoimmune)						
CFTR gene	Cystic Fibrosis						
Ocular gene	Inherited retinal disease						
AZD1222	COVID-19 Vaccine						

Process development and bioprocessing revenues, and royalties

Orchard therapeutics
Beam Therapeutics
ARCELLX
Cabaletta Bio
Boehringer Ingelheim
Santen
AstraZeneca [1]

In vivo programmes *Ex vivo programmes*

1. Scale up and vaccine manufacturing revenues

Oxford Biomedica

Oxford Biomedica
Gene Therapeutics Pipeline

Product	Indication	Pre-Clinical	Phase I/II	Phase II	Phase III
OXB Partnered Products					
Axo-Lenti-PD[1]	Parkinson's disease				Development milestones and royalties
OXB Proprietary Unencumbered Products					
OXB-302	Acute Myeloid Leukaemia				
OXB-40X	Undisclosed liver indications				
OXB-40Y					
OXB-40Z					

In vivo programmes *Ex vivo programmes*

1. AXO-LENTI-PD formerly known as OXB-102, which OXB out-licensed to Sio Gene Therapies